BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioMarin Pharmaceutical Inc (BMRN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals, with technical indicators being neutral to slightly positive, but insider selling, competitive headwinds, and declining financial metrics raise concerns. While the company has growth potential in the long term due to acquisitions and pipeline developments, the current entry point does not present a compelling opportunity given the investor's impatience and unwillingness to wait for optimal conditions.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 47.147, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 61.944, with key support at 58.722 and resistance at 65.167. Overall, the technical indicators suggest a neutral to slightly bullish trend.
Revenue growth of 13% YoY in
Completion of the Inozyme acquisition and expected closing of the Amicus acquisition, which could strengthen the pipeline.
Analysts highlight potential undervaluation and upcoming catalysts like Phase 3 readouts and pipeline updates.
Insider selling has increased significantly by 1502.12% in the last month.
Competitive headwinds for key product Voxzogo, with upcoming challengers in the market.
Declining financial metrics, including a drop in net income (-137.28% YoY) and EPS (-135.94% YoY).
Mixed analyst ratings with some price target downgrades and concerns about future growth.
In Q4 2025, revenue increased by 14.99% YoY to $859.32M, but net income dropped by 137.28% YoY to -$46.57M, and EPS fell by 135.94% YoY to -$0.23. Gross margin also declined by 16.33% YoY to 67.35%. While revenue growth is positive, the significant decline in profitability metrics raises concerns.
Analyst ratings are mixed. Some firms like Bernstein and Oppenheimer maintain Outperform ratings with price targets in the $90-$95 range, citing undervaluation and growth potential. However, others like H.C. Wainwright and Guggenheim have lowered price targets due to competitive risks and soft guidance for Voxzogo. The consensus reflects cautious optimism but highlights significant risks.
